CYP19A1 and neoplasm: It is likely that the resistance of the tumor to the aromatase inhibitor Anastrozole can be explained by the mutant ESR1. This mutation was confirmed in a CLIA laboratory and anti-Estrogen Receptor treatments were considered between cfDNA sequencing and patient death.